SCHEMBL3035586

SCHEMBL3035586

COc1n[nH]c2c1CCOc1cc(N3C[C@H](C(N)=O)OC3=O)ccc1-2

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.41
PIK3CA P42336 5/20 0.36
SIGMAR1 Q99720 2/20 0.35
TGFBR1 P36897 2/20 0.35
ACVR1 Q04771 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.32
HTR6 P50406 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
DRD1 P21728 1/20 0.31
FADS1 O60427 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3040569 0.91 SIGMAR1 (0.34) MAOASIGMAR1TGFBR1ACVR1L3MBTL1
SCHEMBL3038300 0.90 SIGMAR1 (0.34) MAOASIGMAR1TGFBR1ACVR1L3MBTL1
SCHEMBL3045561 0.88 MAOA (0.41) MAOAPIK3CASIGMAR1LMNAALDH1A1
SCHEMBL3042185 0.86 MAOA (0.41) MAOAPIK3CATDP1KMT2A
SCHEMBL3038601 0.86 MAOA (0.39) MAOASIGMAR1HTR6MEN1KMT2A
SCHEMBL3048388 0.82 MAOA (0.34) MAOA
SCHEMBL3029325 0.81 MAOA (0.41) MAOAPIK3CA
SCHEMBL13515913 0.80 MAOA (0.38) MAOAPIK3CA
SCHEMBL3043079 0.79 MAOA (0.45) MAOAPIK3CASIGMAR1KMT2A
SCHEMBL3048193 0.78 ALDH1A1 (0.34) MAOASIGMAR1L3MBTL1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US claimed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-7141588-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER, INC. (US) 2006-11-28 US disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAOA 957/4885PIK3CA 2855/4885SIGMAR1 1597/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAOA 957/4885PIK3CA 2855/4885SIGMAR1 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.